Imatinib

Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions

← predicts response to

PDGFRA Fusionfusion

sensitivity

Curated

Myeloproliferative Neoplasm

← predicts response to

PDGFRB Fusionfusion

sensitivity

Curated

← predicts response to

KIT Exon 9 Mutation

sensitivity

Curated

← predicts response to

KIT Exon 11 Mutation

sensitivity

Curated

← predicts response to

PDGFRA D842VSNV

3 source records aggregated

resistance

Curated

Gastrointestinal Stromal Tumor,Melanoma

← predicts response to

KIT Exon 11 Mutation

2 source records aggregated

sensitivity

Curated

← predicts response to

KIT EXPRESSIONexpression

sensitivity

Curated

← predicts response to

KIT Exon 9 Mutation

resistance

Curated

← predicts response to

KIT D816VSNV

resistance

Systemic Mastocytosis

Curated

← predicts response to

KIT D816VSNV

sensitivity

Systemic Mastocytosis

Curated

← predicts response to

KIT Exon 9 Mutation

sensitivity

Curated

← predicts response to

KIT Amplificationamplification

resistance

Mucosal Melanoma

Curated

← predicts response to

KIT Mutationother

sensitivity

Curated

← predicts response to

IKZF1 Deletiondeletion_cna

sensitivity

Curated

Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions

← predicts response to

PDGFRA Fusionfusion

sensitivity

Curated

← predicts response to

BCL2L11 Deletion Polymorphismdeletion

resistance

Curated

← predicts response to

ABL1 Fusionfusion

resistance

Curated

← predicts response to

ABL1 T315ISNV

resistance

Curated

← predicts response to

ABL1 Fusionfusion

21 source records aggregated

resistance

Curated

B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like

← predicts response to

PDGFRB Fusionfusion

5 source records aggregated

sensitivity

Curated

← predicts response to

ABL1 G250ESNV

2 source records aggregated

resistance

Curated

← predicts response to

ABL1 F359VSNV

2 source records aggregated

resistance

Curated

Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions

← predicts response to

PDGFRA Fusionfusion

2 source records aggregated

resistance

Curated

Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions

← predicts response to

PDGFRA T674ISNV

2 source records aggregated

resistance

Curated

Malignant Endometrial Neoplasm

← predicts response to

KIT EXPRESSIONexpression

2 source records aggregated

sensitivity

Curated

B Lymphoblastic Leukemia/Lymphoma,B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like

← predicts response to

ABL1 Fusionfusion

2 source records aggregated

sensitivity

Curated

← predicts response to

ABL1 L364ISNV

resistance

Curated

← predicts response to

ABL1 M244VSNV

resistance

Curated

← predicts response to

ABL1 E98GSNV

resistance

Curated

← predicts response to

ABL1 D363GSNV

resistance

Curated

← predicts response to

ABL1 Fusionfusion

resistance

Curated

← predicts response to

PDGFRA V561DSNV

sensitivity

Curated

← predicts response to

KIT K484_G487DELdeletion

sensitivity

Curated

← predicts response to

ABL1 P-Loop Mutation

resistance

Curated

← predicts response to

ABL1 E459KSNV

resistance

Curated

← predicts response to

ABL1 F486SSNV

resistance

Curated

← predicts response to

KIT K642ESNV

sensitivity

Mucosal Melanoma

Curated

← predicts response to

ABL1 H396RSNV

resistance

Curated

← predicts response to

ABL1 S417YSNV

resistance

Curated

← predicts response to

ABL1 F317LSNV

resistance

Curated

← predicts response to

ABL1 L248VSNV

resistance

Curated

← predicts response to

PDGFRA D842VSNV

resistance

Curated

← predicts response to

KIT Exon 13 Mutation

sensitivity

Curated

← predicts response to

KIT T417_D419delinsYindel

sensitivity

Curated

← predicts response to

KIT M541LSNV

sensitivity

Chronic Leukemia

Curated

B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like

← predicts response to

CSF1R Fusionfusion

sensitivity

Curated

← predicts response to

ABL1 Fusionfusion

sensitivity

Curated

← predicts response to

ABL1 Fusionfusion

sensitivity

Curated

← predicts response to

ABL1 Y253FSNV

resistance

Curated

← predicts response to

ABL1 E355GSNV

resistance

Curated

B Acute Lymphoblastic Leukemia

← predicts response to

PDGFRA Fusionfusion

sensitivity

Curated

← predicts response to

KIT V559DSNV

sensitivity

Curated

← predicts response to

KIT T670ISNV

resistance

Curated

← predicts response to

KIT D816HSNV

resistance

Curated

← predicts response to

KIT D820GSNV

resistance

Curated

← predicts response to

KIT D820ASNV

resistance

Curated

← predicts response to

KIT C809GSNV

resistance

Curated

← predicts response to

KIT Y823DSNV

resistance

Curated

← predicts response to

KIT N822KSNV

resistance

Curated

← predicts response to

KIT D820YSNV

resistance

Curated

← predicts response to

ABL1 T315ISNV

resistance

Curated

← predicts response to

ABL1 E255VSNV

resistance

Curated

← predicts response to

ABL1 Q252HSNV

resistance

Curated

← predicts response to

PDGFRA Mutationother

sensitivity

Curated

Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions

← predicts response to

PDGFRA Fusionfusion

sensitivity

Curated

Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions

← predicts response to

PDGFRA Fusionfusion

sensitivity

Curated

← predicts response to

KIT Internal Duplicationinsertion

sensitivity

Anal Melanoma

Curated

← predicts response to

ABL1 Double Ph

resistance

Curated

← predicts response to

ABL1 M351TSNV

resistance

Curated

← predicts response to

ABL1 E255KSNV

resistance

Curated

← predicts response to

KIT V560DELdeletion

sensitivity

Thymus Carcinoma

Curated

Acute Lymphoblastic Leukemia,Acute Myeloid Leukemia,Chronic Myeloid Leukemia, BCR-ABL1 Positive+1

← predicts response to

ABL1 Fusionfusion

30 source records aggregated

resistance

Curated

Acute Lymphoblastic Leukemia,Chronic Myeloid Leukemia, BCR-ABL1 Positive,Malignant Neoplasm

← predicts response to

ABL1 T315ISNV

6 source records aggregated

resistance

Curated

Chronic Myeloid Leukemia, BCR-ABL1 Positive,Malignant Neoplasm

← predicts response to

ABL1 Fusionfusion

4 source records aggregated

sensitivity

Curated

Chronic Myeloid Leukemia, BCR-ABL1 Positive,Malignant Neoplasm

← predicts response to

ABL1 F317LSNV

4 source records aggregated

resistance

Curated

Chronic Myeloid Leukemia, BCR-ABL1 Positive,Malignant Neoplasm

← predicts response to

KIT D816VSNV

3 source records aggregated

resistance

Curated

Chronic Myeloid Leukemia, BCR-ABL1 Positive,Malignant Neoplasm

← predicts response to

ABL1 Y253FSNV

3 source records aggregated

resistance

Curated

Chronic Myeloid Leukemia, BCR-ABL1 Positive,Malignant Neoplasm

← predicts response to

ABL1 G250ESNV

3 source records aggregated

resistance

Curated

← predicts response to

ABL1 E255KSNV

3 source records aggregated

resistance

Curated

Gastrointestinal Stromal Tumor,Malignant Neoplasm

← predicts response to

KIT V559DSNV

2 source records aggregated

sensitivity

Curated

Lung Non-Small Cell Carcinoma,Malignant Neoplasm

← predicts response to

KIT L576PSNV

2 source records aggregated

sensitivity

Curated

← predicts response to

ABL1 H396RSNV

2 source records aggregated

resistance

Curated

← predicts response to

ABL1 M351TSNV

2 source records aggregated

sensitivity

Curated

Gastrointestinal Stromal Tumor,Malignant Neoplasm

← predicts response to

PDGFRA D842VSNV

2 source records aggregated

resistance

Curated

← predicts response to

KIT S628NSNV

sensitivity

Curated

← predicts response to

KIT K550_W557deldeletion

sensitivity

Curated

← predicts response to

ABL1 D276GSNV

resistance

Curated

← predicts response to

ABL1 L248VSNV

resistance

Curated

← predicts response to

ABL1 F359VSNV

resistance

Curated

← predicts response to

PDGFRA I843DELdeletion

sensitivity

Curated

← predicts response to

KIT Mutationother

sensitivity

Curated

← predicts response to

ABL1 M244VSNV

resistance

Curated

← predicts response to

ABL1 Q252HSNV

resistance

Curated

← predicts response to

ABL1 H396PSNV

resistance

Curated

← predicts response to

ABL1 T315ASNV

resistance

Curated

← predicts response to

ABL1 M351TSNV

resistance

Curated

← predicts response to

ABL1 Fusionfusion

resistance

Curated

← predicts response to

KIT V560GSNV

sensitivity

Curated

← predicts response to

KIT K558delinsNPindel

sensitivity

Curated

← predicts response to

KIT V560DSNV

sensitivity

Curated

← predicts response to

KIT W557_K558deldeletion

sensitivity

Curated

← predicts response to

ABL1 Q252HSNV

sensitivity

Curated

← predicts response to

ABL1 M244VSNV

sensitivity

Curated

← predicts response to

sensitivity

Curated

← predicts response to

sensitivity

Curated

← predicts response to

sensitivity

Curated

← predicts response to

sensitivity

Curated

← predicts response to

PDGFRA V561ASNV

sensitivity

Curated

Acute Lymphoblastic Leukemia

← predicts response to

CSF1R Fusionfusion

sensitivity

Curated

← predicts response to

KIT V654ASNV

resistance

Curated

← predicts response to

KIT L576PSNV

resistance

Curated

← predicts response to

KIT A829PSNV

resistance

Curated

← predicts response to

KIT N822KSNV

resistance

Curated

← predicts response to

KIT W557_K558deldeletion

resistance

Curated

← predicts response to

KIT V560_L576deldeletion

sensitivity

Curated

← predicts response to

KIT D816ESNV

resistance

Curated

← predicts response to

KIT T670ISNV

resistance

Curated

Lung Non-Small Cell Carcinoma

← predicts response to

ABL1 R351WSNV

sensitivity

Curated

← predicts response to

KIT M541LSNV

sensitivity

—

Curated

Imatinib targets …TARGETS4 of 4
→ targets	KIT	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	BCR	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	ABL1	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	PDGFRB	—	INHIBITOR	—	1	Curated	chembl	graph →

Imatinib targets …TARGETS4 of 4

→ targets

KIT

—

INHIBITOR

—

Curated

→ targets

BCR

—

INHIBITOR

—

Curated

→ targets

ABL1

—

INHIBITOR

—

Curated

→ targets

PDGFRB

—

INHIBITOR

—

Curated

Imatinib investigated for …INVESTIGATED_FOR15 of 93show all (up to 200)
→ investigated for	Gastrointestinal Stromal Tumorsubtype 2 source records aggregated	supports	A	Gastrointestinal Stromal Tumor	2	Curated	civic	graph →
→ investigated for	Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype 2 source records aggregated	supports	A	Chronic Myeloid Leukemia, BCR-ABL1 Positive	2	Curated	civic	graph →
→ investigated for	Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusionshematologic_malignancy	supports	A	Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions	1	Curated	civic	graph →
→ investigated for	Myeloproliferative Neoplasmhematologic_malignancy	supports	A	Myeloproliferative Neoplasm	1	Curated	civic	graph →
→ investigated for	Acute Myeloid Leukemiahematologic_malignancy	supports	A	Acute Myeloid Leukemia	1	Curated	civic	graph →
→ investigated for	Gastrointestinal Stromal Tumorsubtype 7 source records aggregated	supports	B	Gastrointestinal Stromal Tumor	7	Curated	civic	graph →
→ investigated for	Systemic Mastocytosishematologic_malignancy 2 source records aggregated	supports	B	Systemic Mastocytosis	2	Curated	civic	graph →
→ investigated for	Melanomacancer_family 2 source records aggregated	supports	B	Melanoma	2	Curated	civic	graph →
→ investigated for	Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype 2 source records aggregated	supports	B	Chronic Myeloid Leukemia, BCR-ABL1 Positive	2	Curated	civic	graph →
→ investigated for	Mucosal Melanomahistology	supports	B	Mucosal Melanoma	1	Curated	civic	graph →
→ investigated for	B Lymphoblastic Leukemia/Lymphomahematologic_malignancy	supports	B	B Lymphoblastic Leukemia/Lymphoma	1	Curated	civic	graph →
→ investigated for	Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusionshematologic_malignancy	supports	B	Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions	1	Curated	civic	graph →
→ investigated for	Myelodysplastic/Myeloproliferative Neoplasmhematologic_malignancy	unknown	4	Myelodysplastic/Myeloproliferative Neoplasm	1	Curated	chembl	graph →
→ investigated for	Dermatofibrosarcoma Protuberanssubtype	unknown	4	Dermatofibrosarcoma Protuberans	1	Curated	chembl	graph →
→ investigated for	Gastrointestinal Stromal Tumorsubtype	unknown	4	Gastrointestinal Stromal Tumor	1	Curated	chembl	graph →

Imatinib investigated for …INVESTIGATED_FOR15 of 93show all (up to 200)

→ investigated for

2 source records aggregated

supports

Curated

→ investigated for

Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype

2 source records aggregated

supports

Curated

Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions

→ investigated for

Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusionshematologic_malignancy

supports

Curated

Myeloproliferative Neoplasm

→ investigated for

Myeloproliferative Neoplasmhematologic_malignancy

supports

Curated

→ investigated for

Acute Myeloid Leukemiahematologic_malignancy

supports

Acute Myeloid Leukemia

Curated

→ investigated for

7 source records aggregated

supports

Curated

→ investigated for

Systemic Mastocytosishematologic_malignancy

2 source records aggregated

supports

Systemic Mastocytosis

Curated

→ investigated for

Melanomacancer_family

2 source records aggregated

supports

Curated

→ investigated for

Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype

2 source records aggregated

supports

Curated

→ investigated for

Mucosal Melanomahistology

supports

Mucosal Melanoma

Curated

→ investigated for

B Lymphoblastic Leukemia/Lymphomahematologic_malignancy

supports

Curated

Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions

→ investigated for

Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusionshematologic_malignancy

supports

Curated

Myelodysplastic/Myeloproliferative Neoplasm

→ investigated for

Myelodysplastic/Myeloproliferative Neoplasmhematologic_malignancy

unknown

Curated

Dermatofibrosarcoma Protuberans

→ investigated for

Dermatofibrosarcoma Protuberanssubtype

unknown

Curated

→ investigated for

unknown

Curated

Imatinib investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 77show all (up to 200)
→ investigated in trials for	Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype 41 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Myeloid Leukemia, BCR-ABL1 Positive	41	Observed	clinicaltrials	graph →
→ investigated in trials for	Gastrointestinal Stromal Tumorsubtype 27 trials (9 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Gastrointestinal Stromal Tumor	27	Observed	clinicaltrials	graph →
→ investigated in trials for	Leukemia 16 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Leukemia	16	Observed	clinicaltrials	graph →
→ investigated in trials for	Myeloid Leukemia 16 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Myeloid Leukemia	16	Observed	clinicaltrials	graph →
→ investigated in trials for	Acute Lymphoblastic Leukemiahematologic_malignancy 11 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Acute Lymphoblastic Leukemia	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype 8 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Melanomacancer_family 6 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Melanoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Acute Myeloid Leukemiahematologic_malignancy 4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Acute Myeloid Leukemia	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Myelomonocytic Leukemia 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Myelomonocytic Leukemia	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Hematopoietic and Lymphoid Cell Neoplasm 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hematopoietic and Lymphoid Cell Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Sarcoma 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Sarcoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Acute Lymphoblastic Leukemia 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Acute Lymphoblastic Leukemia	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Eosinophilic Leukemia, Not Otherwise Specifiedhematologic_malignancy 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Eosinophilic Leukemia, Not Otherwise Specified	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Breast Neoplasm 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	2	Observed	clinicaltrials	graph →

Imatinib investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 77show all (up to 200)

→ investigated in trials for

Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype

41 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

→ investigated in trials for

27 trials (9 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

→ investigated in trials for

Leukemia

16 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Leukemia

Observed

→ investigated in trials for

Myeloid Leukemia

16 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Myeloid Leukemia

Observed

Acute Lymphoblastic Leukemia

→ investigated in trials for

Acute Lymphoblastic Leukemiahematologic_malignancy

11 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

→ investigated in trials for

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype

8 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

→ investigated in trials for

Melanomacancer_family

6 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

→ investigated in trials for

Acute Myeloid Leukemiahematologic_malignancy

4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Acute Myeloid Leukemia

Observed

Chronic Myelomonocytic Leukemia

→ investigated in trials for

3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Chronic Myelomonocytic Leukemia

Observed

Hematopoietic and Lymphoid Cell Neoplasm

→ investigated in trials for

3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Hematopoietic and Lymphoid Cell Neoplasm

Observed

→ investigated in trials for

Sarcoma

3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Sarcoma

Observed

Adult Acute Lymphoblastic Leukemia

→ investigated in trials for

2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Adult Acute Lymphoblastic Leukemia

Observed

Chronic Eosinophilic Leukemia, Not Otherwise Specified

→ investigated in trials for

Chronic Eosinophilic Leukemia, Not Otherwise Specifiedhematologic_malignancy

2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive

→ investigated in trials for

2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive

Observed

Malignant Breast Neoplasm

→ investigated in trials for

2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Breast Neoplasm

Observed

Imatinib studied in …STUDIED_INderived10 of 174show all (up to 200)
→ studied in	NCT06090669Phase 1 · recruiting Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency · 174 trials list this drug (36 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT06124157Phase 2 · recruiting A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) · 174 trials list this drug (36 active)	—	—	B Acute Lymphoblastic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT07585266Phase 3 · recruiting A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) · 174 trials list this drug (36 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT05152472Phase 2 · recruiting A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments · 174 trials list this drug (36 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT05816785early Phase 1 · completed Pilot Study of Imatinib Cetuximab Combo for H & N Cancer · 174 trials list this drug (36 active)	—	—	Malignant Head and Neck Neoplasm,Head and Neck Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03722420Phase 3 · active not recruiting Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) · 174 trials list this drug (36 active)	—	—	Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive	1	Observed	clinicaltrials	graph →
→ studied in	NCT05493215Phase 2 · recruiting Imatinib TDM in GIST · 174 trials list this drug (36 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT04971226Phase 3 · active not recruiting A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP · 174 trials list this drug (36 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT04838041Phase 2 · recruiting Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation · 174 trials list this drug (36 active)	—	—	Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive	1	Observed	clinicaltrials	graph →
→ studied in	NCT03906292Phase 2 · active not recruiting Frontline Asciminib Combination in Chronic Phase CML · 174 trials list this drug (36 active)	—	—	Chronic Myeloid Leukemia, BCR-ABL1 Positive	1	Observed	clinicaltrials	graph →

Imatinib studied in …STUDIED_INderived10 of 174show all (up to 200)

→ studied in

NCT06090669Phase 1 · recruiting

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency · 174 trials list this drug (36 active)

—

not mapped

Observed

B Acute Lymphoblastic Leukemia

→ studied in

NCT06124157Phase 2 · recruiting

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) · 174 trials list this drug (36 active)

—

Observed

→ studied in

NCT07585266Phase 3 · recruiting

A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) · 174 trials list this drug (36 active)

—

Observed

→ studied in

NCT05152472Phase 2 · recruiting

A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments · 174 trials list this drug (36 active)

—

Observed

Malignant Head and Neck Neoplasm,Head and Neck Squamous Cell Carcinoma

→ studied in

NCT05816785early Phase 1 · completed

Pilot Study of Imatinib Cetuximab Combo for H & N Cancer · 174 trials list this drug (36 active)

—

Observed

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

→ studied in

NCT03722420Phase 3 · active not recruiting

Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) · 174 trials list this drug (36 active)

—

Observed

→ studied in

NCT05493215Phase 2 · recruiting

Imatinib TDM in GIST · 174 trials list this drug (36 active)

—

Observed

→ studied in

NCT04971226Phase 3 · active not recruiting

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP · 174 trials list this drug (36 active)

—

not mapped

Observed

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

→ studied in

NCT04838041Phase 2 · recruiting

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation · 174 trials list this drug (36 active)

—

Observed

→ studied in

NCT03906292Phase 2 · active not recruiting

Frontline Asciminib Combination in Chronic Phase CML · 174 trials list this drug (36 active)

—

Observed